Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pembrolizumab

Lichenoid dermatitis: case report

    • 6 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Curry JL, et al. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. Journal of Cutaneous Pathology 46: 627-636, No. 9, Sep 2019. Available from: URL: http://doi.org/10.1111/cup.13454

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Pembrolizumab. Reactions Weekly 1791, 211 (2020). https://doi.org/10.1007/s40278-020-75056-5

    Download citation